Compositions and methods for eliciting immune responses with a secretion-directed protein
CA 2354255 A1 · Owner: Gedamu, Lashitew · Inventors: Gedamu, Lashitew; Iatrou, Kostas; Farrell, Patrick J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of nucleic acids which code for secretory, fusion proteins to elicit immune responses. The secretory fusion protein comprises a signal, sequence from a secretion competent protein particularly a cytokine, which is , linked in frame with the coding sequence of the antigen of interest which is normally intracellular. The, nucleic acid encoding such a fusion protein is significantly more effective in its ability to elicit, antibody production than the nucleic acid encoding the intracellular antigen. The present, invention thus provides for a method of generating antibodies as well as a method of eliciting, protective immune response using such …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 8, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 8, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 8, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.